Evidence map›Paper›PMID 38719502›Full record

Observational studyBMJ open respiratory research2024

Association between COVID-19 severity and tobacco smoking status: a retrospective cohort study using propensity score matching weights analysis.

Musaad A Alshammari, Ahmad Alamer, Lina Al Lehaibi, Mashael Alghamdi, Haneen Alotaibi, Mukhtar Alomar, Fawaz Alasmari, Faleh Alqahtani, Abdualziz Alhossan, Tahani K Alshammari

Abstract readObservational Study
In one paragraph

Observational study in BMJ open respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Impact of Smoking on Household SARS-CoV-2 Transmission.Healthcare (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Musaad A AlshammariDepartment of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia malshammari@ksu.edu.sa.ORCID http://orcid.org/0000-0002-5165-1095
Ahmad AlamerDepartment of Clinical Pharmacy, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia.ORCID http://orcid.org/0000-0002-2091-1376
Lina Al LehaibiDepartment of Pharmaceutical Affairs, Dammam Medical Complex, Eastern Health Cluster, Dammam, Saudi Arabia.ORCID http://orcid.org/0000-0003-1117-8675
Mashael AlghamdiResearch Office, Saudi National Institute of Health, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0001-9741-0724
Haneen AlotaibiCollege of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Mukhtar AlomarDepartment of Pharmaceutical Affairs, Dammam Medical Complex, Eastern Health Cluster, Dammam, Saudi Arabia.ORCID http://orcid.org/0000-0001-7798-6881
Fawaz AlasmariDepartment of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0003-2382-5892
Faleh AlqahtaniDepartment of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0003-3924-593X
Abdualziz AlhossanDepartment of Clinical Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0001-5849-6756
Tahani K AlshammariDepartment of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0002-2211-1014

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 pandemic continues to be a global threat to public health, with over 766 million confirmed cases and more than 6 million reported deaths. Patients with a smoking history are at a greater risk of severe respiratory complications and death due to COVID-19. This study investigated the association between smoking history and adverse clinical outcomes among COVID-19 patients admitted to a designated medical centre in Saudi Arabia.

methodsA retrospective observational cohort study was conducted using patient chart review data from a large tertiary medical centre in the eastern region of the country. Patients admitted between January and December 2020 were screened. The inclusion criteria were ≥18 years of age and confirmed COVID-19 infection via reverse-transcription-PCR. The exclusion criteria were unconfirmed COVID-19 infection, non-COVID-19 admissions, unconfirmed smoking status, vaccinated individuals, essential chart information missing or refusal to consent. Statistical analyses comprised crude estimates, matching weights (as the main analysis) and directed acyclic graphs (DAGs) causal pathway analysis using an ordinal regression model.

resultsThe sample comprised 447 patients (never-smoker=321; ever-smoker=126). The median age (IQR) was 50 years (39-58), and 73.4% of the sample were males. A matching weights procedure was employed to ensure covariate balance. The analysis revealed that the odds of developing severe COVID-19 were higher in the ever-smoker group with an OR of 1.44 (95% CI 0.90 to 2.32, p=0.130). This was primarily due to an increase in non-invasive oxygen therapy with an OR of 1.05 (95% CI 0.99 to 1.10, p=0.101). The findings were consistent across the different analytical methods employed, including crude estimates and DAGs causal pathway analysis.

conclusionOur findings suggest that smoking may increase the risk of adverse COVID-19 outcomes. However, the study was limited by its retrospective design and small sample size. Further research is therefore needed to confirm the findings.

Indexed as

COVID-19Propensity ScoreSARS-CoV-2AdultAgedFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSaudi ArabiaSeverity of Illness IndexTobacco SmokingClinical EpidemiologyCOVID-19Non invasive ventilationRespiratory InfectionTobacco and the lung

Identifiers

PMID38719502
PMCPMC11086284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.